Climb Bio director granted options on 40,000 shares

Climb Bio, Inc. director Kimberlee C. Drapkin received a grant of stock options covering 40,000 shares of Common Stock.

Accepted by SEC EDGAR 06/08/2026 - 06:39 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Climb Bio, Inc. director Kimberlee C. Drapkin received a grant of stock options covering 40,000 shares of Common Stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. Following this grant, she holds options on 40,000 shares directly. The options will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, subject to her continued service through that date.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Drapkin Kimberlee C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Key Figures

Option grant size: 40,000 options Exercise price: $10.55 per share Underlying shares: 40,000 shares +3 more

6 metrics

Option grant size 40,000 options Stock Option (Right to Buy) granted to director

Exercise price $10.55 per share Exercise price of stock options

Underlying shares 40,000 shares Common Stock underlying the options

Expiration date June 4, 2036 Option expiration

Post-grant holdings 40,000 derivative shares Total options held after transaction

Vesting date trigger June 5, 2027 or before next annual meeting Earlier of those dates, subject to continued service

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title": "Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price": "10.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"prior to the date of the next annual meeting of stockholders"

continued service financial

"subject to the reporting person's continued service through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Climb Bio (CLYM) report for Kimberlee C. Drapkin?

Climb Bio reported that director Kimberlee C. Drapkin received stock options on 40,000 shares of Common Stock. These options were granted as compensation, not bought on the open market, and represent a new equity incentive tied to her ongoing service.

What is the exercise price and term of the new Climb Bio (CLYM) stock options?

The granted stock options have an exercise price of $10.55 per share and expire on June 4, 2036. This gives the director a long-dated right to buy Climb Bio Common Stock at that fixed price if vesting conditions are met.

How many Climb Bio (CLYM) shares are covered by Kimberlee Drapkin’s new option grant?

The option grant covers 40,000 underlying shares of Climb Bio Common Stock. After this grant, the Form 4 shows Drapkin holding options on 40,000 shares directly, reflecting her entire reported derivative position in this filing.

When do Kimberlee Drapkin’s Climb Bio (CLYM) stock options vest?

The options vest on the earlier of June 5, 2027 or the date immediately before Climb Bio’s next annual stockholder meeting. Vesting is conditioned on Drapkin’s continued service with the company through that applicable vesting date.

Did Kimberlee Drapkin buy or sell any Climb Bio (CLYM) shares in this Form 4?

The Form 4 reports only a grant of stock options, coded as an acquisition (A), and no open-market buys or sells. There were no sales of Common Stock; the transaction strictly reflects compensation-related option awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drapkin Kimberlee C

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MASSACHUSETTS 02481

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.55	06/05/2026		A		40,000		(1)	06/04/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

Remarks:

Exhibit Index: 24.1 - Power of Attorney

	Chandra Adams, as Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)